5 Or 6 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.8)
-
Patent number: 8828940Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.Type: GrantFiled: December 14, 2010Date of Patent: September 9, 2014Assignee: Compugen Ltd.Inventors: Yossi Cohen, Ronen Shemesh, Amir Toporik, Zurit Levine, Assaf Wool, Dvir Dahary, Iris Hecht, Galit Rotman, Michal Ayalon-Soffer
-
Publication number: 20140242108Abstract: A conjugated compound of Formula I: Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a TLR2 agonist, the conjugated compound being chosen among compounds of Formula II:Type: ApplicationFiled: February 22, 2013Publication date: August 28, 2014Applicant: CAYLAInventors: Thierry LIOUX, Daniel DROCOURT, Fabienne VERNEJOUL, Gerard TIRABY, Eric PEROUZEL
-
Patent number: 8816049Abstract: There is provided a lipid peptide that is capable of forming a hydrogel with an extremely small amount thereof over a liquid property range from acidic to alkaline, and a hydrogel having high environmental suitability, biocompatibility and biodegradability. A lipid peptide represented by Formula (1): where R1 represents an aliphatic group having 9 to 23 carbon atoms; R2, R3, R4 and R5 independently represent a hydrogen atom, an alkyl group having 1 to 7 carbon atom(s) which optionally has a branched chain having 1 to 3 carbon atom(s), a phenylmethyl group, a phenylethyl group or a —(CH2)n—X group, and at least one of R2, R3, R4 and R5 represents a —(CH2)n—X group; n represents the number of 1 to 4; X represents a guanidino group, a —CONH2 group or a 5-membered ring, a 6-membered ring or a fused heterocyclic ring composed of a 5-membered ring and a 6-membered ring which optionally have 1 to 3 nitrogen atom(s); and m represents 1 or 2, and a hydrogel comprising the lipid peptide.Type: GrantFiled: November 26, 2012Date of Patent: August 26, 2014Assignees: Nissan Chemical Industries, Ltd., Kyushu UniversityInventors: Nobuhide Miyachi, Takehisa Iwama, Masahiro Gotoh, Tatsuo Maruyama, Daisuke Koda
-
Patent number: 8815806Abstract: The instant invention relates to peptides obtained from the enzymatic hydrolysis of yellow pea seed proteins that are capable of lowering the blood pressure and reducing the effects of kidney disease in a subject by inhibiting or reducing the affinity of the enzymes in the renin-angiotensin system for their substrates, specifically renin, to compositions comprising said peptides and to uses thereof.Type: GrantFiled: October 28, 2010Date of Patent: August 26, 2014Assignee: University of ManitobaInventors: Rotimi Aluko, Jianping Wu, Harold Aukema
-
Publication number: 20140235544Abstract: The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.Type: ApplicationFiled: February 15, 2013Publication date: August 21, 2014Inventor: Yitzchak Hillman
-
Patent number: 8809276Abstract: New peptides activating extracellular matrix protein synthesis in the skin, a cosmetic composition that includes such peptides as an active agent, and cosmetic care methods intended to delay or treat cutaneous signs of aging and photoaging by applying such peptides and/or cosmetic compositions are described.Type: GrantFiled: February 17, 2012Date of Patent: August 19, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8809279Abstract: Peptide compounds of the following general formula (I): R1-(AA)n-X1-X2-X3-Lys-Lys-Gln-Lys-Trp-X4-(AA)p-R2 are disclosed herein. The peptide compounds can be used as Telomeric repeat-binding factor 2 (TRF2) protein-modulating compounds and have a preventive action on deoxyribonucleic acid (DNA) double-strand breaks. In addition, cosmetic compositions that include at least one peptide of general formula (I) in a physiologically acceptable medium are disclosed along with methods for preventing and/or treating cutaneous signs of aging and photoaging.Type: GrantFiled: April 27, 2012Date of Patent: August 19, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8802635Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.Type: GrantFiled: August 9, 2013Date of Patent: August 12, 2014Assignees: Oneday—Biotech And Pharma Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
-
Publication number: 20140220070Abstract: The present invention relates to the use of a composition comprising at least one cell membrane fraction or parts thereof, for the reduction of lipolytic activity and/or to retard fat digestion, suppress appetite, body weight and/or lower blood lipids. The invention also relates to the use of said hydrophobic peptide in a pharmaceutical as well as a food composition and methods of treating a mammal with said composition.Type: ApplicationFiled: December 23, 2013Publication date: August 7, 2014Applicant: Thylabisco ABInventors: Per-Ake ALBERTSSON, Charlotte ERLANSSON-ALBERTSSON
-
Patent number: 8778891Abstract: Peptides activating dermatopontin in the skin and cosmetic compositions including such peptide, in a physiologically suitable medium, are described. Methods of treating the cutaneous signs of aging and photoaging, and in particular wrinkles, sagging, and loss of volume and elasticity of the skin are also described.Type: GrantFiled: November 7, 2011Date of Patent: July 15, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8778376Abstract: A copolymer comprising a block of an elastin pentapeptide and method of making and using the copolymer are provided.Type: GrantFiled: June 9, 2006Date of Patent: July 15, 2014Assignee: Advanced Cardiovascular Systems, Inc.Inventors: Syed F. A. Hossainy, Mikael Trollsas, Thierry Glauser, Yiwen Tang
-
Publication number: 20140194371Abstract: A solid oxidized glutathione salt is produced by heating an oxidized glutathione at 30° C. or higher while the oxidized glutathione is brought into contact with an aqueous medium in the presence of a substance for providing a cation, to produce the salt of the oxidized glutathione and the cation as a solid, wherein the aqueous medium is composed of water and/or a water-soluble medium, and the cation is at least one selected from an ammonium cation, a calcium cation and a magnesium cation.Type: ApplicationFiled: June 28, 2012Publication date: July 10, 2014Applicant: KANEKA CORPORATIONInventors: Taku Mouri, Naoaki Taoka, Tadashi Moroshima, Koichi Kinoshita
-
Patent number: 8772247Abstract: A novel structural class of highly N-methylated linear lipopeptide compounds useful for the treatment of parasitic disease.Type: GrantFiled: March 20, 2010Date of Patent: July 8, 2014Assignee: The Regents of the University of CaliforniaInventors: Roger Linington, Laura Sanchez
-
Publication number: 20140187494Abstract: The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, inhibit the interaction of MUC1 with NF-?B or a STAT, and block inflammatory response mediated by NF-?B or STAT signaling.Type: ApplicationFiled: December 23, 2013Publication date: July 3, 2014Applicants: GENUS ONCOLOGY, LLC, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Donald W. KUFE, Surender KHARBANDA
-
Patent number: 8765689Abstract: Peptide compounds of the general formula (I) R1-(AA)n-X1—X2-Arg-Glu-Met-Asn-Trp-X3-(AA)p-R2 modulating the survivin protein are described. Furthermore, cosmetic or pharmaceutical compositions, including at least one peptide of the general formula (I), in a physiologically acceptable medium are described. Additionally, methods for treating the cutaneous signs of ageing and photo-ageing, treating the skin against external aggressions, and limiting hair loss and/or stimulating hair growth are described.Type: GrantFiled: January 13, 2011Date of Patent: July 1, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20140179616Abstract: Peptides of 5 to 14 amino acids in length that stimulate subcutaneous adipogenesis and uses thereof are provided.Type: ApplicationFiled: November 25, 2013Publication date: June 26, 2014Applicant: The Regents of The University of CaliforniaInventors: EVA A. TURLEY, SEYED BAHRAM BAHRAMI, MINA J. BISSELL
-
Publication number: 20140171373Abstract: Disclosed herein are isolated polypeptides, antibody preparations, treatment methods, diagnostic methods, and screening methods related to tauopathy. Generally, the isolated polypeptide includes a core pentapeptide, with the proviso that the isolated polypeptide is not a native full-length tau protein. Generally, the antibody preparations include antibody that specifically binds to SEQ ID NO:12. Generally, the treatment methods include administering to a subject a composition that includes the isolated polypeptide. Generally, the diagnostic methods includes contacting a sample from a subject with an antibody preparation that includes antibody that specifically binds to SEQ ID NO:12, and then detecting a ligand in the sample that specifically binds the antibody preparation.Type: ApplicationFiled: December 18, 2013Publication date: June 19, 2014Applicant: Regents of the University of MinnesotaInventors: Karen Hsiao Ashe, Xiaohui Zhao, Michael Anthony Walters, Derek John Hook, Morgan Clotaire Paul Le Naour
-
Publication number: 20140171377Abstract: The present invention provides novel peptides that facilitate the opening of mammalian tight junctions, i.e. tight junction agonists. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide tight junction agonist of the invention in combination with a therapeutically effective amount of an active agent.Type: ApplicationFiled: September 10, 2013Publication date: June 19, 2014Applicant: Alba Therapeutics CorporationInventors: Amir Tamiz, Min Li
-
Publication number: 20140161786Abstract: The present invention generally relates to therapeutic compositions for the treatment of mammalian disease and related methods. It more specifically relates to compositions comprising peptides for the treatment of inflammation and methods for delivering the peptides. In one composition aspect, the composition comprises a peptide, and the peptide comprises one or more hexapeptides that are capable of forming fibrils.Type: ApplicationFiled: August 29, 2013Publication date: June 12, 2014Inventors: Jonathan B. Rothbard, Lawrence Steinman, Michael P. Kurnellas
-
Publication number: 20140154192Abstract: The invention provides compounds of formula (I): (I) or salts thereof, wherein R1, R2, R3 Z, and X have any of the values defined herein, as well as compositions comprising such compounds. The compounds and compositions are useful for treating neurodegenerative disorders.Type: ApplicationFiled: July 6, 2012Publication date: June 5, 2014Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: Robert Vince, Swati Sudhakar More
-
Patent number: 8741843Abstract: An isolated peptide comprising an amino acid sequence HWRR as set forth by SEQ ID NO:5, the peptide consists of 4 or 5 amino acids, is provided. Also provided are methods of treating angiogenesis-related pathologies using the peptide of the invention or pharmaceutical compositions comprising same.Type: GrantFiled: May 10, 2012Date of Patent: June 3, 2014Inventors: Britta Hardy, Alexander Battler, Annat Raiter, Chana Weiss
-
Patent number: 8741835Abstract: A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, H-Inp-D-Bal-D-Trp-Phe-Apc-NH2 (SEQ ID NO:73) or other suitable ghrelin agonist, to counteract the catabolic effects of dexamethasone and other natural glucocorticoids.Type: GrantFiled: November 2, 2011Date of Patent: June 3, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Giovanni Tulipano, Andrea Giustina, Zheng Xin Dong, Michael DeWitt Culler
-
Patent number: 8728491Abstract: The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen.Type: GrantFiled: May 7, 2008Date of Patent: May 20, 2014Assignee: Alba Therapeutics CorporationInventors: Dorothea Sesardic, Blake Paterson
-
Publication number: 20140135276Abstract: The invention provides a peptide or peptidomimetic that is derived from or based upon the amino acid sequence of the C-terminal ?-helix or hypervariable region (HVR) or a Ras protein, a nucleic acid encoding the peptide or peptidomimetic, and methods employing the same.Type: ApplicationFiled: May 25, 2012Publication date: May 15, 2014Applicants: CALIDRIS THERAPEUTICS, LTD., The Board of Trustees of the University of Illinois, The United States of America, as represented by the Secretary, Dep. of Health & Human Services, VANDERBILT UNIVERSITYInventors: Nadya I. Tarasova, Sergey G. Tarasov, Vadim Gaponenko, Joseph Kates, Alla Ivanova, Michael C. Dean
-
Patent number: 8722626Abstract: The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.Type: GrantFiled: June 1, 2011Date of Patent: May 13, 2014Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Jorge Berlanga Acosta, Danay Cibrian Vera, Diana Garcia Del Barco Herrera, Gerardo Enrique Guillén Nieto, José Suarez Alba, Ernesto Lopez Mola, Manuel Selman-Housein Sosa, Mariela Vazquez Castillo
-
Patent number: 8722627Abstract: A peptidic hydrolyzate enriched in bioactive peptides is disclosed that is a proteasome activator. Cosmetic and pharmaceutical compositions are disclosed that include the peptidic hydrolyzate enriched in bioactive peptides in a physiologically acceptable medium. Also disclosed are methods for depigmenting, lightening and/or whitening the skin and treating hyperpigmentation blemishes as well as cutaneous signs due to photo-aging by administering the cosmetic compositions or pharmaceutical compositions.Type: GrantFiled: April 22, 2010Date of Patent: May 13, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8722629Abstract: The present application relates to novel derivatives of monomethylauristatin F, to processes for preparing these derivatives, to the use of these derivatives for treating and/or preventing diseases, and also to the use of these derivatives for preparing medicaments for treating and/or preventing diseases, more particularly hyperproliferative and/or angiogenic disorders such as, for example, cancerous disorders. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: June 6, 2011Date of Patent: May 13, 2014Assignee: Seattle Genetics, Inc.Inventors: Hans-Georg Lerchen, Beatrix Stelte-Ludwig, Sven Golfier, Joachim Schuhmacher, Ursula Krenz
-
Patent number: 8710011Abstract: Peptides of general formula (I): R1-Wp-Xn-AA1-AA2-AA3-AA4-Ym-R2 their stereoisomers, mixtures thereof, and/or their cosmetically or pharmaceutically acceptable salts, a method of preparation, cosmetic or pharmaceutical compositions containing them and their use for the treatment, prevention and/or care of conditions, disorders and/or diseases of the skin, mucous membranes and/or scalp.Type: GrantFiled: February 16, 2010Date of Patent: April 29, 2014Assignee: Lipotec, S.A.Inventors: Nuria Garcia Sanz, Wim Van Den Nest, Cristina Carreno Serraima, Antonio Ferrer Montiel, Juan Cebrian Puche, Nuria Alminana Domenech
-
Publication number: 20140113875Abstract: The present invention provides herein the design of monodisperse, amphiphilic anticancer drugs—which are now termed “drug amphiphiles” (DAs)—that can spontaneously associate into discrete, stable supramolecular nanostructures with the potential for self-delivery (no additional carriers are needed). The quantitative drug loading in the resulting nanostructures is ensured by the very nature of the molecular design. The DA is a composition comprising: D-L-PEP; wherein D is 1 to 4 hydrophobic drug molecules which can be the same or different; L is 1 to 4 biodegradable linkers which can be the same or different; and PEP is a peptide that can spontaneously associate into discrete, stable supramolecular nanostructures. In an alternate embodiment, the DA composition also comprises a targeting ligand (T). Methods of making DA molecules, as well as their use in treatment of disease are also provided.Type: ApplicationFiled: October 2, 2013Publication date: April 24, 2014Applicant: The Johns Hopkins UniversityInventors: Honggang Cui, Andrew G. Cheetham, Pengcheng Zhang
-
Patent number: 8697635Abstract: The present application relates to a pharmaceutical preparation to be administered into respiratory organs for treating or preventing inflammatory respiratory diseases, comprising a peptide which acts on formyl peptide receptors (FPRs) or receptors analogous thereto, in an amount which is effective in suppressing respiratory inflammation. The present application also relates to a method for treating or preventing inflammatory respiratory diseases by using the preparation, and to a kit containing the preparation. As compared with systemic administration of the peptide by injection, direct administration of the peptide to respiratory organs remarkedly improves the effect in suppressing respiratory inflammation.Type: GrantFiled: May 12, 2010Date of Patent: April 15, 2014Assignee: Postech Academy-Industry FoundationInventors: Yoon Keun Kim, Yong Song Gho, You Me Tae, Yoe Sik Bae, Sung Ho Ryu
-
Patent number: 8691247Abstract: The subject invention relates to a skin cream that can be used to moisturize and rejuvenate skin that has been damaged by exposure to sunlight or which has simply been affected over the years by intrinsic aging. It inhibits the formation of wrinkles and in some cases reduces the depth of existing wrinkles or eliminates them entirely. This invention is based upon the discovery that alkyl lactates, such as ethyl lactate, can be used to improve the penetration of active ingredients in skin care formulations deep into lower layers of the skin tissue. The present invention more specifically discloses a topical formulation comprising ascorbic acid, an amino acid selected from the group consisting of phenylalanine and tyrosine, a non-toxic zinc salt, an alkyl lactate, and a pharmaceutically acceptable carrier.Type: GrantFiled: December 17, 2007Date of Patent: April 8, 2014Assignee: Ad Lunam Labs Inc.Inventors: William H. Beeson, Alvin T. Rockhill
-
Publication number: 20140093473Abstract: The present invention provides an amphiphilic linear peptide and/or peptoid as well as a hydrogel that includes the amphiphilic linear peptide/peptoid.Type: ApplicationFiled: December 31, 2012Publication date: April 3, 2014Inventors: Charlotte Hauser, Yihua Loo
-
Publication number: 20140088023Abstract: The present invention provides materials and methods useful to treat various sGC?1-expressing cancers. Materials include peptides which interfere with sGC?1's pro-survival functions, thereby resulting in apoptosis of sGC?1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.Type: ApplicationFiled: November 1, 2013Publication date: March 27, 2014Applicant: THE UNIVERSITY OF TOLEDOInventors: Lirim Shemshedini, Shao-Yong Chen, Changmeng Cai, Chen-Lin Hsieh
-
Patent number: 8673862Abstract: Peptides useful as angiotensin converting enzyme inhibitors are provided. Also provided are compositions comprising one or more of the peptides and methods for preventing, treating and/or diminishing one or more syndromes associated with angiotensin converting enzyme by using the peptides.Type: GrantFiled: September 6, 2012Date of Patent: March 18, 2014Assignee: Food Industry Research and Development InstituteInventors: Yi-Hong Chen, Hsiang-Ling Lai, Shiao-Cheng Chuang, Chien-Ti Chang, Ming-Yu Hung, Yu-Hui Liu, Su-Er Liou, Fu-Ning Chien, Chu-Chin Chen
-
Patent number: 8674060Abstract: Loss of Wnt-5a protein expression in breast carcinoma patients is associated with a shorter recurrence-free survival as well as increased motility in mammary cell lines. Based on sequence analysis of Wnt-5a, peptide fragments were identified and investigated for their ability to mimic effects of the Wnt-5a protein on mammary cell adhesion and motility. Two of these peptides significantly increased adhesion and impaired the motility of non-tumorigenic breast cancer cell lines, both low in endogenous Wnt-5a protein expression. To identify the shortest possible peptide that still had an anti-motile effect, sequential deletions of two amino acids from the N-terminal side of the shorter of these two peptides were performed. The effect on tumor cell adhesion was gradually lost, and when only 6 amino acids remained the effect was not detectable. However, formulation of the N-terminal methionine of this hexapeptide restored its effect on adhesion and reduced tumor cell motility.Type: GrantFiled: November 28, 2007Date of Patent: March 18, 2014Assignee: Wntresearch ABInventor: Tommy Andersson
-
Publication number: 20140066361Abstract: Peptides useful as angiotensin converting enzyme inhibitors are provided. Also provided are compositions comprising one or more of the peptides and methods for preventing, treating and/or diminishing one or more syndromes associated with angiotensin converting enzyme by using the peptides.Type: ApplicationFiled: September 6, 2012Publication date: March 6, 2014Applicant: FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTEInventors: YI-HONG CHEN, HSIANG-LING LAI, SHIAO-CHENG CHUANG, CHIEN-TI CHANG, MING-YU HUNG, YU-HUI LIU, SU-ER LIOU, FU-NING CHIEN, CHU-CHIN CHEN
-
Publication number: 20140065175Abstract: The invention relates to the technological sector of the transport and delivery of molecules into cells, either at cytoplasm or at nucleus or inter-cells (cell to cell transport), using peptides binding proteins from the cell microtubule motor complex, preferably dynein-binding peptides, as carrier/delivery peptides; or functionalized structures, as nanoparticles, linked to said carrier/delivery peptides. This delivery can be useful in many technical fields comprising, among some others: diagnosis, therapy and pharmacology.Type: ApplicationFiled: February 17, 2012Publication date: March 6, 2014Inventors: M. Covadonga Alonso Martí, José Ángel Martínez Escribano
-
Patent number: 8660753Abstract: The present invention relates to a control method of a wheel alignment apparatus using an MDPS, which determines whether or not to cancel center alignment control due to a trouble or error is preferentially determined prior to each control step and then performs control when wheels of a vehicle having an MDPS mounted therein are aligned, such that the trouble or error is preferentially considered in the control priority, thereby increasing driver's convenience and improving safety performance for protecting the driver.Type: GrantFiled: May 2, 2013Date of Patent: February 25, 2014Assignee: Hyundai Mobis Co., Ltd.Inventor: Jeong Ku Kim
-
Publication number: 20140045768Abstract: The invention provides tight junction protein modulators, compositions comprising the same, and uses thereof. In particular, the invention provides tight junction protein modulators that modulate the second extracellular loop of tight junction proteins, such as occludin or claudin.Type: ApplicationFiled: October 21, 2013Publication date: February 13, 2014Applicant: The Regents of the University of Colorado, a body corporateInventors: Margaret C. Neville, Neal Beeman, Robert S. Hodges
-
Publication number: 20140045759Abstract: Compositions that include isolated peptides that inhibit TLR-4 signaling pathways and inflammation are disclosed. Methods of producing and using the compositions to inhibit TLR-4 signaling and/or inflammation are also disclosed herein.Type: ApplicationFiled: August 30, 2013Publication date: February 13, 2014Applicant: The Board of Regents of the University of OklahomaInventor: Shanjana Awasthi
-
Publication number: 20140045753Abstract: The present invention relates to novel polypeptides, methods for their synthesis, pharmaceutical compositions comprising the novel polypeptides as well as their use in medicaments for therapeutic applications.Type: ApplicationFiled: October 15, 2013Publication date: February 13, 2014Applicant: NOVO NORDISK HEALTH CARE AGInventors: Bernd Peschke, Magali Zundel
-
Publication number: 20140044655Abstract: This invention relates to new peptides activating extracellular matrix protein synthesis in the skin. This invention also relates to a cosmetic composition comprising such peptides as an active agent and the use of such a composition for increasing the extracellular matrix protein expression, delaying the appearance of or reducing wrinkles, sagging and loss of skin volume, and dehydration of the skin. The invention finally relates to cosmetic care methods intended to delay or treat cutaneous signs of aging and photoaging.Type: ApplicationFiled: February 17, 2012Publication date: February 13, 2014Applicant: ISP INVESTMENTS INC.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20140037560Abstract: This invention relates to peptide compounds of general formula (I) R1-(AA)n-X1—X2—X3-Asp-Leu-Lys-Lys-X4—X5-(AA)p-R2. Said peptide compounds have an action on the SCF/c-Kit signaling pathway and thus make it possible to protect skin pigment structures from external stresses. In addition, this invention relates to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I), in a physiologically acceptable medium, and its use for attenuating age-related pigmentation defects and the effects of photoaging on the skin. The invention finally relates to various cosmetic treatment methods using said peptides according to the invention.Type: ApplicationFiled: January 30, 2012Publication date: February 6, 2014Applicant: ISP INVESTMENTS INC.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20140038898Abstract: Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications.Type: ApplicationFiled: March 16, 2012Publication date: February 6, 2014Applicant: Duke UniversityInventors: Daniel T. Laskowitz, Hana Dawson, Brad Kolls
-
Patent number: 8642561Abstract: A generic structure for the peptides of the present invention includes A-X-B-C, where C is a cargo moiety, the B portion includes basic amino acids, X is a cleavable linker sequence, and the A portion includes acidic amino acids. The intact structure is not significantly taken up by cells; however, upon extracellular cleavage of X, the B-C portion is taken up, delivering the cargo to targeted cells. Cargo may be, for example, a contrast agent for diagnostic imaging, a chemotherapeutic drug, or a radiation-sensitizer for therapy. Cleavage of X allows separation of A from B, unmasking the normal ability of the basic amino acids in B to drag cargo C into cells near the cleavage event. X is cleaved extracellularly, preferably under physiological conditions. D-amino acids are preferred for the A and B portions, to minimize immunogenicity and nonspecific cleavage by background peptidases or proteases.Type: GrantFiled: December 7, 2011Date of Patent: February 4, 2014Assignee: The Regents of the University of CaliforniaInventors: Tao Jiang, Roger Y. Tsien
-
Patent number: 8642044Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.Type: GrantFiled: August 20, 2007Date of Patent: February 4, 2014Assignee: Janssen Alzheimer ImmunotherapyInventors: Dale B. Schenk, Nicki Vasquez, Theodore Yednock
-
Patent number: 8642729Abstract: The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases.Type: GrantFiled: April 7, 2009Date of Patent: February 4, 2014Assignee: Institut PasteurInventor: Catherine Rougeot
-
Publication number: 20140030321Abstract: The invention described herein pertains to a solid pharmaceutical composition comprising EC145 for reconstitution to provide a solution for intravenous injection, particularly to a lyophilized solid pharmaceutical composition comprising EC145 which has adequate stability for storage at ambient temperature and which is capable of redissolving in an aqueous diluent prior to administration, as well as a process for its manufacture, drug products comprising the composition and methods for using the composition for treating cancer.Type: ApplicationFiled: April 12, 2012Publication date: January 30, 2014Applicant: ENDOCYTE, INC.Inventors: Allen Ritter, Amy C. Williams, Lars Waldmann, Huamin Zhang
-
Publication number: 20140024596Abstract: At least one peptide molecule selected from EGDGHLGKPGROGE (SEQ ID NO:1), EKDGHPGKPGROGE (SEQ ID NO:2), G(POG)4, (POG)3, G(POG)2, (POG)2, (POG)4, (POG)5 and G(POG)3, and pharmaceutically acceptable salts thereof is effective for inhibiting various diseases such as osteoporosis, osteoarthritis and pressure ulcer. The peptide molecule is easily absorbed into a body and migrates into cells in an intestinal tract, and strongly binds to a nucleic acid compound or the like to form a complex, and thus functions well as a carrier component for delivering the nucleic acid compound or the like without causing the problems associated with conventional DDS techniques.Type: ApplicationFiled: June 11, 2013Publication date: January 23, 2014Inventors: Fumihito SUGIHARA, Naoki INOUE, Hiroshi MANO
-
Publication number: 20140024606Abstract: Novel peptidomimetics comprising N-amino cyclic urea residues are disclosed.Type: ApplicationFiled: June 5, 2013Publication date: January 23, 2014Inventors: WILLIAM D. LUBELL, SYLVAIN CHEMTOB, HUY ONG, ROBERT HOPEWELL, CAROLINE PROULX, KIM BEAUREGARD, YESICA GARCIA-RAMOS, NGOC-DUC DOAN